2024 guidance for organic sales growth excluding COVID diagnostics is now 8.5-10%, up from the prior guidance of 8-10%.
2024 guidance for non-GAAP EPS (which excludes FX and restructuring costs) is now $4.55-$4.70, up from the prior guidance of $4.50-4.70.
1Q24 non-GAAP and GAAP EPS were $0.98 and $0.70, respectively, versus $1.03 and $0.59 in 1Q23. The YoY decline in non-GAAP EPS was due to lower sales of COVID diagnostics, which were $204M in 1Q24 vs $730M in 1Q23.
4Q23 FreeStyle Libre sales were $1.5B, +23% YoY in constant currency. FreeStyle Libre is the largest-selling medical device, ever, from any company.
Please see #msg-174255202 for a breakdown of ABT’s 1Q24 sales by business segment.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.